Haemonetics Corp.
HAE
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.93B
Close$
$89.81
17.2% downside
Current Fair Value
17.2% downsideOvervalued by 17.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.93 Billion |
|---|---|
| Enterprise Value | $5.88 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.05 |
| Beta | 0.54 |
| Outstanding Shares | 45,361,000 |
Return
| Return on Equity | 11.50% |
|---|---|
| Return on Assets | 4.07% |
| Return on Invested Capital | 7.19% |
Valuation & Multiples
| P/E Ratio | 52.63 |
|---|---|
| PEG | -1754.25 |
| Price to Sales | 3.74 |
| Price to Book Ratio | 6.03 |
| Enterprise Value to Revenue | 4.35 |
| Enterprise Value to EBIT | 38.89 |
| Enterprise Value to Net Income | 61 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | 1.4 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$1.08
Average shareholder expectationRevenue Estimate
$327.86 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$1.30
Average shareholder expectationRevenue Estimate
$345.15 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3301▼ 9.53% |
|---|---|
| Total Calls | 354,100▲ 234.06% |
| Total Puts | 116,900▲ 159.20% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 110.80%▲ 9.86% |
|---|---|
| Total Invested | $3.76B▲ 40.16% |
| Investors Holding | 342▲ 10.00% |
ESG Score
No data
About Haemonetics Corp.
CEO: Christopher Simon